Article Text

Download PDFPDF

Original article
Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2
  1. Iain B McInnes1,
  2. Soumya D Chakravarty2,3,
  3. Isabel Apaolaza4,
  4. Shelly Kafka2,
  5. Elizabeth C Hsia5,6,
  6. Yin You7 and
  7. Arthur Kavanaugh8
  1. 1Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK
  2. 2Immunology Medical Affairs, Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA
  3. 3Drexel University, College of Medicine, Philadelphia, Pennsylvania, USA
  4. 4Medical Affairs, Janssen Biologics BV, Leiden, The Netherlands
  5. 5Immunology, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA
  6. 6Division of Rheumatology, University of Pennslyvania, Philadelphia, Pennsylvania, USA
  7. 7Biostatistics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA
  8. 8Department of Medicine, University of California, San Diego, School of Medicine, La Jolla, California, USA
  1. Correspondence to Iain B McInnes; iain.mcinnes{at}glasgow.ac.uk

Abstract

Objective To evaluate the efficacy of ustekinumab by prior treatment exposure and disease duration in tumour necrosis factor inhibitor (TNF)-naïve patients with psoriatic arthritis (PsA) in the PSUMMIT 1 and PSUMMIT 2 studies.

Methods In the phase 3, randomised, placebo-controlled PSUMMIT 1 and PSUMMIT 2 studies, adults with active PsA for ≥6 months despite conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or non-steroidal anti-inflammatory drugs (NSAIDs) (PSUMMIT 1) or csDMARDs, NSAIDs and/or anti-TNF agents (PSUMMIT 2) were enrolled. Patients were randomised to subcutaneous injections of placebo, ustekinumab 45 mg or ustekinumab 90 mg at weeks 0 and 4 and every 12 weeks. Efficacy was assessed at week 24 using the American College of Rheumatology criteria and 28-joint count disease activity score using C reactive protein (DAS28-CRP); radiographical progression, enthesitis, and dactylitis were also assessed in this post hoc analysis.

Results A total of 747 patients were included; all 747 were TNF-naïve, of which, 179 were methotrexate-naïve and TNF-naïve, and 146 were all csDMARD-naïve and TNF-naïve. At week 24, greater proportions of ustekinumab-treated patients had ≥20%/50%/70% improvement in American College of Rheumatology criteria (ACR20/ACR50/ACR70) responses, DAS28-CRP response and DAS28-CRP remission versus placebo in all three prior-treatment populations, with similar differences between treatment groups. Greater proportions of ustekinumab-treated patients also had complete resolution of enthesitis and dactylitis at week 24 across the three prior-treatment populations. Mean changes from baseline in total van der Heijde-Sharp Score at week 24 were generally smaller for ustekinumab-treated patients versus placebo but were statistically significant only in the full TNF-naïve population. Response rates for ACR20/ACR50/ACR70 were similar for TNF-naïve patients with PsA durations of <1 year, ≥1 to <3 years, and ≥3 years.

Conclusion Ustekinumab-treated patients demonstrated greater clinical response at week 24 compared with placebo regardless of prior treatment exposure and PsA disease duration.

  • psoriatic arthritis
  • ustekinumab
  • anti-Il-12, anti-Il-23
  • biologics

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors All authors contributed to the study design, YY conducted the data analysis, and all authors interpreted the data and revised the manuscript.

  • Funding This study was funded by Janssen Research & Development, LLC.

  • Competing interests IBM has received consulting fees from AbbVie, Celgene, Janssen, Novartis, Pfizer and UCB. AK has received consulting fees and research support from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer and UCB. IA is an employee of Janssen Biologics BV. SDC and SK are employees of Janssen Scientific Affairs, LLC, and own stock in Johnson & Johnson, of which Janssen Scientific Affairs, LLC, is a wholly owned subsidiary. ECH and YY are employees of Janssen Research & Development, LLC, and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly owned subsidiary.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.